

TABLE 1. Anti-inflammatory agents that provide significant cardiovascular risk reduction

Target	Agent	Trial	Number of participants
IL-1b	Canakinumab	CANTOS	10,061
NLRP3 inflammasome	Colchicine	LoDoCo	532
NLRP3 inflammasome	Colchicine	COLCOT	4,745
NLRP3 inflammasome	MCC950	Encouraging results in preclinical models	

Abbreviations: IL-1b: interleukin 1b, NLRP3: nucleotide-binding domain (NOD)-like receptor protein 3, CANTOS: Canakinumab Anti-Inflammatory Thrombosis Outcomes trial, LoDoCo: Low Dose Colchine trial, COLCOT: Colchicine Cardiovascular Outcomes trial